001). The significant BP reduction was apparent from month 1 and continued throughout the study Combretastatin A4 molecular weight period of 6 months. Fig. 3 Effect of LOS/HCTZ on home BP (all patients). SBP systolic blood pressure, DBP diastolic blood pressure, LOS/HCTZ losartan/hydrochlorothiazide, ANOVA one-way analysis of variance Changes find more in laboratory tests Table 2 shows changes in various parameters at the beginning and end of the observation period. There was an increase in serum Cr concentration (84.9 ± 34.5 to 89.3 ± 38.9 μmol/L, P < 0.001) in conjunction with a decrease in eGFR (from

65.6 ± 21.2 to 63.4 ± 20.7 mL/min/1.73 m2, P < 0.001). Additionally, there was a significant decrease in serum sodium (Na) concentration (from 141.5 ± 2.1 to 140.8 ± 2.7 mEq/L, P < 0.001). No changes were found in blood lipids and serum potassium (K) concentration. Table 2 Laboratory tests before and after the treatment with LOS/HCTZ   Baseline 6 months P value selleckchem s-Cr (μmol/L) 84.9 ± 34.5 89.3 ± 38.9 <0.001 Na (mmol/L) 141.5 ± 2.1

140.8 ± 2.0 <0.001 K (mmol/L) 4.3 ± 0.6 4.3 ± 0.6 0.940 LDL-C (mmol/L) 3.0 ± 0.7 3.0 ± 0.7 0.356 HDL-C (mmol/L) 1.5 ± 0.4 1.5 ± 0.4 0.118 TG (mmol/L) 1.9 ± 1.5 1.9 ± 1.3 0.938 Hb (g/L) 139 ± 18 139 ± 17 0.903 Ht (%) 42.1 ± 4.5 41.8 ± 4.6 0.141 RBC (×1012/L) 4.49 ± 0.5 4.47 ± 0.51 0.428 WBC (×109/L) 6.2 ± 1.7 6.3 ± 1.8 0.508 Platelets (×109/L) 232 ± 55 233 ± 55 0.670 eGFR(mL/min/1.73 m2) 65.6 ± 21.2 63.4 ± 20.7 <0.001 Laboratory tests before (baseline) and after (6 months) the treatment with LOS/HCTZ s-Cr serum creatinine concentration,

Na serum sodium concentration, K serum potassium concentration, LDL-C LDL cholesterol, HDL-C HDL cholesterol, TG triglyceride, Hb hemoglobin, Ht hematocrit, eGFR estimated glomerular PAK5 filtration rate Figure 4 depicts changes in BNP after switching from the original prescription to LOS/HCTZ ridden regimen. The overall median BNP level significantly decreased from 18.8 to 15.4 pg/dL (P < 0.05). In patients whose BNP at baseline was more than 18.4 pg/dL (above the normal range, n = 96), the median level of BNP also decreased from 34.4 to 25.4 pg/dL (P < 0.01). Fig. 4 Changes in BNP in response to LOS/HCTZ. BNP B-type natriuretic peptide, LOS/HCTZ losartan/hydrochlorothiazide Figure 5 shows the BNP response as a function of BP response. In 135 responders defined as a reduction in systolic BP of ≥10 mmHg, the median BNP fell from 21.7 to 14.4 pg/dL (P < 0.05), whereas there was no change in BNP in 93 non-responders whose systolic BP reduction was less than 10 mmHg. Fig. 5 Changes in BNP classified by BP response. Responders were defined as patients whose systolic BP reduction was more than 10 mmHg. LOS/HCTZ losartan/hydrochlorothiazide Figure 6 shows changes in ACR. The overall median value decreased from 21.7 to 13.9 mg/gCr (P < 0.05). In patients whose baseline ACR more than 30 mg/gCr (above the abnormal range, n = 67), the median value decreased from 108.0 to 52.0 mg/gCr (P < 0.01). Fig.